by Clinical Neuropsychologist Online | Tuesday, September 15, 2026 | Dementia
Abstract INTRODUCTION Lysosomal dysfunction contributes to Alzheimer’s disease (AD) by impairing protein clearance and promoting neuroinflammation. Cathepsin H (CTSH), a lysosomal protease, recently emerged as a protective AD locus. We investigated how CTSH is...
by Clinical Neuropsychologist Online | Tuesday, September 15, 2026 | Dementia
Abstract INTRODUCTION Amyloid positivity does not reliably predict near-term cognitive decline in preclinical Alzheimer’s disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision. METHODS Baseline performance on a brief...
by Clinical Neuropsychologist Online | Tuesday, September 15, 2026 | Dementia
Abstract As cardiac surgery becomes more common, concerns about postoperative cognitive decline and the potential progression to dementia have grown. While postoperative cognitive dysfunction (POCD) is well documented, its relationship to long-term dementia risk...
by Clinical Neuropsychologist Online | Tuesday, September 15, 2026 | Dementia
Abstract INTRODUCTION Our goal was to determine Alzheimer’s disease (AD) and related dementias (ADRD) incidence and risk factors among American Indian and Alaska Native (AI/AN) veterans, an understudied group. METHODS We identified AI/AN veterans ≥ 55 years...
by Clinical Neuropsychologist Online | Sunday, September 13, 2026 | Dementia
Abstract INTRODUCTION Postmenopausal estrogen decline may contribute to Alzheimer’s disease (AD), but evidence linking circulating estrogens to cerebrospinal fluid (CSF) AD biomarkers remains limited. METHODS We analyzed 854 female participants from the European...
by Clinical Neuropsychologist Online | Sunday, September 13, 2026 | Dementia
Abstract INTRODUCTION Vascular cognitive impairment and dementia (VCID) is a common cause of cognitive impairment, yet validated biomarkers, particularly those reflecting vascular function, remain lacking. Oxygen extraction fraction (OEF), which reflects the...
